Racivir

Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI) developed by Pharmasset for the treatment of HIV infection. It is a small molecule and a cytidine analog that acts as a chain terminator during viral DNA synthesis. Racivir is a racemic (50:50) mixture of emtricitabine and its positive enantiomer. Its mechanism of action involves inhibition of the HIV reverse transcriptase enzyme by competing with endogenous nucleotides for incorporation into viral DNA; once incorporated, it prevents further elongation due to the absence of a 3'-hydroxyl group on its sugar moiety. Racivir has been studied in clinical trials for use in patients with resistance to other NRTIs such as lamivudine and has shown antiviral activity particularly in individuals harboring certain resistance mutations (e.g., M184V). It remains investigational and has not received regulatory approval[1][2][3][4][5][6].

Brand names

Racivir

Other names

4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one4-Amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one